CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis
Abstract Inhibitors of cyclin-dependent kinases 4/6 (CDK4/6) block cell cycle progression and are commonly used for treatment of several forms of cancer. Due to their anti-proliferative mode of action, we hypothesized that palbociclib could attenuate the development of bleomycin-induced lung fibrosi...
Main Authors: | Anna Birnhuber, Bakytbek Egemnazarov, Valentina Biasin, Ehsan Bonyadi Rad, Malgorzata Wygrecka, Horst Olschewski, Grazyna Kwapiszewska, Leigh M. Marsh |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-07-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12931-020-01433-w |
Similar Items
-
CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
by: Mattia Garutti, et al.
Published: (2021-05-01) -
Inhibiting CDK4/6 in pancreatic ductal adenocarcinoma via microRNA-21
by: Maria Mortoglou, et al.
Published: (2023-06-01) -
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines
by: Graziana Digiacomo, et al.
Published: (2020-09-01) -
CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
by: Yi-Bo Hou, et al.
Published: (2019-08-01) -
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
by: Lisa Scheiblecker, et al.
Published: (2020-11-01)